Therapeutic Expertise
Click on each therapeutic area below to learn more.
Cardiovascular/
REnal/Metabolic
Central Nervous System
Dermatology
INTERNAL
MEDICINE
Oncology
Cardiovascular/
REnal/Metabolic
Central Nervous System
Dermatology
Oncology
Oncology
A clinical development partner with the right therapeutic expertise can help you optimize the strategy and execution of your programs through their understanding of biomarker development, clinical trial design and execution, and novel delivery scenarios. At IQVIA Biotech, our extensive oncology expertise, coupled with the ability to leverage IQVIA’s vast data, technology and analytics resources, creates a clinical development partner like no other. You want to get the right treatments to the right patients. We want to help you pave a more predictable path to get there.
I am delighted to work alongside biotech sponsors in the exciting world of oncology drug development. We experience the highs and lows with our customers, and nothing is more rewarding than helping a customer successfully bring a new treatment to patients.
Gerhard du Toit
Global Head, Oncology, IQVIA Biotech
*Studies conducted in the last five years among biotech and emerging companies.
500+
Oncology
studies
135+
Hematologic
Oncology studies
66
Countries
140+
Immuno-oncology studies
Trial Expertise by Phase
Phase I
61%
24%
Phase II
14%
Phase III
1%
Phase IV
Central nervous system
Successful CNS drug development requires a clinical development partner that understands the complexities of this broad area, each indication representing a specialty of its own. Our teams have specific CNS experience and strong knowledge of the challenges expected when implementing CNS clinical trials and how to mitigate them. We apply scientific, medical and operational expertise coupled with data-driven methods and tools for realistic strategic planning which allows for more precise predictive models to complete studies on time and on budget.
*Studies conducted since 2011
500+
CNS
studies
260+
Psychiatry
studies
80
Countries
Trial Expertise by Phase
Phase I
30%
20%
Phase II
36%
Phase III
14%
Phase IV
Our CVRM team has operational experience and expertise across a broad spectrum of chronic and acute indications. From acute coronary syndrome, heart failure, kidney disease and diabetes, to hyperlipidemia, and more, we have strong existing investigator relationships and institutional knowledge of operational best practices. Our deep CVRM expertise and focus on biotech customers, combined with integrated real world data, creates a clinical development partnership to help you bring treatments to patients, faster.
I am personally excited by recent progress in demonstrating improved cardiovascular and renal outcomes with some classes of diabetes medications which is leading to more holistic treatment for CVRM disease. Much of the cutting-edge research is being conducted by small biotech sponsors, driving progress within this field.
Scott Oakes, PhD
Vice President, CVRM Therapeutic Division, IQVIA Biotech
*Studies conducted in the last five years.
320+
CVRM studies
175+
Cardiovascular studies
100+
Endocrinology studies
79
Countries
85
Countries
Phase I
10%
14%
Phase II
51%
Phase III
25%
Phase IV
Cardiovascular/Renal/Metabolic
Internal Medicine
*Studies conducted in the last five years.
There is no “one size fits all” model for clinical trials and this is especially true within internal medicine. IQVIA Biotech has experience working in many subspecialties that require therapeutically aligned experts to develop and deliver the optimal clinical strategy. The expertise and experience required to run a cystic fibrosis trial versus an ulcerative colitis trial starts with understanding the differences in the regulatory landscape, clinical trial design, standards of care, competing trials, and having established relationships with key opinion leaders in each specialty area.
Our extensive therapeutic experience, coupled with our flexible operational model and ability to leverage IQVIA’s unparalleled data assets, allows us to partner with biotech customers to help bring treatments to patients as quickly as possible.
TBD
TBD,
TBD
185+
Gastrointestinal studies
105
Countries
Trial Expertise by Phase
Phase I
14%
27%
Phase II
42%
Phase III
17%
Phase IV
*Studies conducted in the last five years.
Dermatology
You require a clinical development partner with deep dermatology expertise and meaningful relationships with key sites around the globe. Our dedicated teams are led by in-house, board-certified dermatologists and have decades of experience conducting early and late phase studies for dermatologic conditions and aesthetics. We apply scientific, medical and operational expertise coupled with data-driven methods and tools for realistic strategic planning which allows for more precise predictive models to complete studies on time and on budget.
TBD
TBD,
TBD
200+
Dermatology studies
45+
Atopic Dermatitis studies
51
Countries
Trial Expertise by Phase
Phase I
15%
36%
Phase II
40%
Phase III
9%
Phase IV
Therapeutic Expertise
Click on each therapeutic area below to learn more.
Cardiovascular/
REnal/Metabolic
Central Nervous System
Dermatology
Immunology
Oncology
Oncology
A clinical development partner with the right therapeutic expertise can help you optimize the strategy and execution of your programs through their understanding of biomarker development, clinical trial design and execution, and novel delivery scenarios. At IQVIA Biotech, our extensive oncology expertise, coupled with the ability to leverage IQVIA’s vast data, technology and analytics resources, creates a clinical development partner like no other. You want to get the right treatments to the right patients. We want to help you pave a more predictable path to get there.
Oncology has been my passion since grad school when I learned the incredible complexity and challenge to tackle cancer within the body. Innovative science begins with small biotechs; I find energy and fulfillment in supporting an industry that helps improve the lives of patients fighting cancer.
Andrew Zupnick, PhD,
Vice President, Oncology Strategy, IQVIA Biotech
*Studies conducted in the last five years among biotech and emerging companies.
>475
Oncology
studies
>125
Hematological
oncology studies
65
Countries
>95
Immuno-oncology studies
Trial Expertise by Phase
Phase I
56%
26%
Phase II
16%
Phase III
2%
Phase IV
Central nervous system
Successful CNS drug development requires a clinical development partner that understands the complexities of this broad area, each indication representing a specialty of its own. Our teams have specific CNS experience and strong knowledge of the challenges expected when implementing CNS clinical trials and how to mitigate them. We apply scientific, medical and operational expertise coupled with data-driven methods and tools for realistic strategic planning which allows for more precise predictive models to complete studies on time and on budget.
*Studies conducted in the last five years.
>300
CNS
studies
~40
Alzheimer’s
Studies
74
Countries
Trial Expertise by Phase
Phase I
16%
26%
Phase II
52%
Phase III
6%
Phase IV
Cardiovascular/Renal/Metabolic
Our CVRM team has operational experience and expertise across a broad spectrum of chronic and acute indications. From acute coronary syndrome, heart failure, kidney disease and diabetes, to hyperlipidemia, and more, we have strong existing investigator relationships and institutional knowledge of operational best practices. Our deep CVRM expertise and focus on biotech customers, combined with integrated real world data, creates a clinical development partnership to help you bring treatments to patients, faster.
I am personally excited by recent progress in demonstrating improved cardiovascular and renal outcomes with some classes of diabetes medications which is leading to more holistic treatment for CVRM disease. Much of the cutting-edge research is being conducted by small biotech sponsors, driving progress within this field.
Scott Oakes, PhD
Senior Director, CVRM Therapeutic Division, IQVIA Biotech
*Studies conducted in the last five years.
~200
CVRM studies
>110
Cardiovascular studies
~65
Endocrinology Studies
79
Countries
77
Countries
Trial Expertise by Phase
Phase I
9%
22%
Phase II
55%
Phase III
14%
Phase IV
Cardiovascular/Renal/Metabolic
Immunology
Trial Expertise by Phase
Phase I
13%
38%
Phase II
43%
Phase III
6%
Phase IV
Dermatology
Being a leader in dermatology research, combined with our flexible operational model, enables us to deliver trials efficiently in terms of cost and time. At IQVIA Biotech, we can leverage technology and specialized expertise and services to bolster our therapeutic offering, while continuing to align with the expectations and needs of our small biotech and biopharma customers. The seamless integration of these elements helps our customers to drive enhanced value, access and health outcomes around the world.
*Studies conducted in the last five years.
TBD
TBD,
TBD
~125
Dermatology studies
~15
Atopic dermatitis Studies
45
Countries
Trial Expertise by Phase
Phase I
20%
39%
Phase II
36%
Phase III
5%
Phase IV
250+
Rare disease studies
100+
Immunology studies
45+
Women's health studies
INTERNAL
MEDICINE
Trial Expertise
Trial Expertise
Subspecialties
Subspecialties
• Gastrointestinal
• Hematology
• Hepatology
• Immunology
• Infectious Disease
• NASH
• Ophthalmology
• Rare Disease
• Respiratory
• Transplant
• Women's Health
Subspecialties
Trial Expertise
Subspecialities
Diabetes
studies
85+
800+
Neurology
studies
100+
Rare neurology studies
50+
Psoriasis studies
25+
Aesthetics
studies
35+
Cellular Therapy studies
100+
Endocrinology studies
460+
CNS
studies
50+
Alzheimer’s
Studies
200+
Dermatology studies
45+
Atopic dermatitis studies
120+
Immuno-oncology studies
Trial Expertise by Phase
Learn More
Learn More
Learn More
Learn More